Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 23 Apr 2023
The treatment of chronic thromboembolic pulmonary hypertension with balloon pulmonary angioplasty has an evolving safety profile over the years, from 2013 to 2022, as revealed by an analysis of more than two dozen studies.
Read Full NewsThe AAN's new guideline enhances diagnosis and management of functional seizures, emphasizing psychological interventions and addressing care gaps for better patient outcomes.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 30, 2026.
Mallon explains the shared risks linking celiac disease and type 1 diabetes and why early screening improves outcomes.
Nedelkopoulou emphasizes the importance of structured and multidisciplinary transition programs for young patients with IBD and HPB disease.
FDA Accepts Oxylanthanum Carbonate NDA Resubmission for Hyperphosphatemia in CKD, Dialysis
6 Nephrology Headlines You Missed In January 2026
OptIMMize-1: New Efficacy and Safety Data on Risankizumab in Pediatric Psoriasis
1.
Patients With Melanoma Brain Mets May Fare Better With RT Before Immunotherapy
2.
Opposition to the Surgical Lymph Node Sampling Rule for Lung Resection.
3.
Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL
4.
Axatilimab Demonstrates Effectiveness in Refractory/Recurrent GVHD.
5.
Young adults who are obese are at risk for 17 different types of cancer in the future.
1.
Precision Oncology: Cancer Screening, Genetic Counseling & Hereditary Cancer Syndromes Integration
2.
Cancer Memory: A Persistent Threat to Tumor Recurrence and Metastasis
3.
Studying Lactic Acid in Pediatric Tumor Microenvironments: Experimental Approaches Explored
4.
The Statistical Paradigm of Leukemia: From Evolving Epidemiology and Molecular Stratification to Precision Therapies and Future Horizons in Leukemia
5.
The Immunotherapeutic and Targeted Revolution in Melanoma Management – A 2025 Perspective
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII
4.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
5.
Navigating the Complexities of Ph Negative ALL - Part XIII
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge